Cancer Clinical Trial
— AYA-PACTOfficial title:
Adolescents and Young Adults Becoming Physically Active After Cancer Trial
In this randomized controlled trial the investigators will determine whether a mobile health intervention can increase physical activity levels in AYA cancer survivors over a one year period. The investigators will recruit 320 cancer survivors in Alberta who were diagnosed with a first cancer between the ages of 15 to 39 years and are within one year of treatment completion. Participants will be randomized into either the control group (educational information) or the intervention group (educational information; personalized physical activity plan; activity tracker watch; access to a private, online survivor community; motivational text messages and check-in calls/e-mails). All participants will complete fitness testing and questionnaires at baseline, 6 months and 12 months. A final measurement at 24 months will test long-term effectiveness.
Status | Recruiting |
Enrollment | 320 |
Est. completion date | September 2026 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years to 39 Years |
Eligibility | Inclusion Criteria: - Lives in Alberta - Diagnosed with invasive malignancy in Alberta - Completed active cancer directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention) in the last 12 months, except for "maintenance" therapy to prevent recurrences - Have the ability to read, write and speak English - Have access to the Internet on at least a weekly basis - Have a mobile phone with a text messaging plan - Willing to be randomized to either arm. Exclusion Criteria: - Health problems which preclude the ability to walk for physical activity, as measured by the Physical Activity Readiness Questionnaire (PAR-Q) - Currently pregnant or planning to become pregnant within the next 6 months - Currently taking part in > 300 minutes/week of moderate-to-vigorous intensity physical activity on a regular basis |
Country | Name | City | State |
---|---|---|---|
Canada | Holy Cross Centre | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
AHS Cancer Control Alberta | University of Calgary |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in weekly minutes of moderate-vigorous intensity physical activity | Measured by Actigraph | Baseline, 6 months, 12 months, 24 months | |
Secondary | Changes in weekly minutes of sedentary time | Measured by Actigraph | Baseline, 6 months,12 months | |
Secondary | Changes in weekly minutes of sleep | Measured by Actigraph | Baseline, 6 months,12 months | |
Secondary | Changes in the Pittsburgh Sleep Quality Index (PSQI) Global Sleep Quality Score | Global score range is 0 to 23 where higher scores indicate worse sleep quality | Baseline, 6 months,12 months | |
Secondary | Changes in weight | Measured in kilograms | Baseline, 6 months,12 months | |
Secondary | Changes in body mass index (BMI) | Measured by combining height (meters) and weight (kilograms) and reported in kg/m2 | Baseline, 6 months,12 months | |
Secondary | Changes in waist and hip circumference | Measured in centimeters | Baseline, 6 months,12 months | |
Secondary | Changes in cardiorespiratory fitness | Measured by peak oxygen consumption in relative (ml/kg/min) values using the incremental Balke and Ware treadmill test with direct measures of gas exchange and ventilation | Baseline, 6 months,12 months | |
Secondary | Changes in cardiorespiratory fitness | Measured by peak oxygen consumption in absolute (L/min) values using the incremental Balke and Ware treadmill test with direct measures of gas exchange and ventilation | Baseline, 6 months,12 months | |
Secondary | Changes in grip strength | Measured in kilograms using a hand dynamometer | Baseline, 6 months,12 months | |
Secondary | Changes in upper body muscular strength | Measured in kilograms using an 8-10 repetition maximum (RM) chest press test used to predict 1-RM | Baseline, 6 months,12 months | |
Secondary | Changes in upper body muscular endurance | Measured in kilograms using the maximum number of chest press repetitions completed at 50-70% of estimated 1-RM | Baseline, 6 months,12 months | |
Secondary | Changes in lower body muscular strength | Measured in kilograms using an 8-10 repetition maximum (RM) leg press test used to predict 1-RM | Baseline, 6 months,12 months | |
Secondary | Changes in lower body muscular endurance | Measured in kilograms using the maximum number of leg press repetitions completed at 50-70% of estimated 1-RM | Baseline, 6 months,12 months | |
Secondary | Changes in frailty | Defined according to the Fried phenotype which takes into account low lean muscle mass, exhaustion, low energy expenditure, walking limitations, and weakness | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Mental Health Component subscale | Score range is from 0 to 100 where higher scores indicate better mental health | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Physical Health Component subscale | Score range is from 0 to 100 where higher scores indicate better physical health | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Physical Functioning subscale | Score range is from 0 to 100 where higher scores indicate higher functioning | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Role-physical subscale | Score range is from 0 to 100 where higher scores indicate higher functioning | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Bodily Pain subscale | Score range is from 0 to 100 where higher scores indicate less pain | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) General Health subscale | Score range is from 0 to 100 where higher scores indicate better health | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Vitality subscale | Score range is from 0 to 100 where higher scores indicate higher vitality | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Social Functioning subscale | Score range is from 0 to 100 where higher scores indicate higher functioning | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 (SF-36) Role-emotional subscale | Score range is from 0 to 100 where higher scores indicate higher functioning | Baseline, 6 months,12 months | |
Secondary | Changes in the Short Form 36 Mental Health subscale | Score range is from 0 to 100 where higher scores indicate better mental health | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Impact of Cancer subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Physical subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Emotional subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Cognitive subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Cancer Worry subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Employment subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Education subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Cancer Distress Scales for AYAs Practical subscale | Scores range from 0 to 100 where higher scores indicate more distress | Baseline, 6 months,12 months | |
Secondary | Changes in the Functional Assessment of Cancer Therapy Cognitive Function Perceived Cognitive Impairment subscale | Score range is from 0 to 80. Higher scores indicate poorer quality of life. | Baseline, 6 months,12 months | |
Secondary | Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Comments From Others subscale | Score range is from 0 to 16 where higher scores indicate poorer cognition | Baseline, 6 months,12 months | |
Secondary | Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Perceived Cognitive Abilities subscale | Score range is from 0 to 36 where higher scores indicate poorer cognition | Baseline, 6 months,12 months | |
Secondary | Changes in the Functional Assessment of Cancer Therapy Cognitive Function (FACT-Cog) Impact on Quality of Life subscale | Score range is from 0 to 16 where higher scores indicate poorer cognition | Baseline, 6 months,12 months | |
Secondary | Changes in the Functional Assessment of Cancer Therapy Fatigue (FACT-F) | Score range is from 0 to 52 where higher scores indicate less fatigue | Baseline, 6 months,12 months | |
Secondary | Changes in the Comprehensive Score for Financial Toxicity (COST) | Score range is from 0 to 44 where higher scores indicate better financial wellbeing | Baseline, 6 months,12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|